Marie Svedberg is Associate Professor in Medical Science at Sophiahemmet University. She has a background as a pharmacist and extensive research experience in medical science, with a focus on biomedical mechanisms in neurological and neurodegenerative diseases.
Following her PhD, she conducted postdoctoral research focusing on neuroimaging techniques, primarily preclinical positron emission tomography (PET), and on the development of potential biomarkers to visualize disease progression in the brain.
Her research includes projects within neurological and neurodegenerative diseases, as well as neuropsychiatric conditions such as depression and bipolar disorder, with emphasis on biomarkers and pharmacological related aspects of disease mechanisms and inflammatory processes.
The overall aim of her research is to contribute to increased knowledge of how pharmacological treatment and biomarkers influence disease progression and function, thereby supporting the development of evidence-based, individualized and clinically relevant care.
Current projects
Marie works with clinical trials in the role of study coordinator, primarily in ear, nose and throat diseases, where biological drugs are used for the treatment of chronic inflammation. The projects aim to link biological markers to clinical outcomes and quality of life while contributing to the development of more individualized treatment strategies.
She is also involved in studies examining stress and inflammatory biomarkers in chronic inflammation, as well as in register-based research assessing the effects and adverse events of common pharmacological therapies in older patients with neuropsychiatric and neurodegenerative conditions.
In ongoing diabetes research, she is involved in studies evaluating person-centred care, continuous glucose monitoring (CGM), and AI-based technologies for their impact on glycaemic control, patient engagement, and well-being.
Her current research focuses on register-based studies investigating the associations between pharmacological treatment (including polypharmacy) and persistent neurological and psychological symptoms post-stroke, including fatigue, cognitive impairment, depression, and pain, as well as the impact of different treatment patterns relating to work ability and return to work